Julie A. Margenthaler, MD

home / authors / julie-margenthaler-md

Articles

38 Comparing Risk Stratification and Radiotherapy Benefit for Patients With DCIS Using a 7-Gene Biosignature as Compared to a Clinicopathologic Nomogram

Julie A. Margenthaler, MD;Karuna Mittal;Frank A. Vicini, MD;Chirag Shah, MD;Rachel Rabinovitch, MD;Pat W. Whitworth;Brian Czerniecki;David J. Dabbs;G. Bruce Mann;Fredrik Wärnberg;Sheila Weinmann;Michael Leo;Steven C. Shivers;Troy Bremer

April 26th 2023

39 7-Gene Predictive Biosignature Improves Risk Stratification for Breast Ductal Carcinoma In Situ Patients Compared to Clinicopathologic Criteria, Identifying a Low-Risk Group Not Clinically Benefiting from Adjuvant Radiotherapy

Rachel Rabinovitch, MD;Frank A. Vicini, MD;Chirag Shah, MD;Julie A. Margenthaler, MD;Brian Czerniecki;Pat W. Whitworth;David J. Dabbs;G. Bruce Mann;Fredrik Wärnberg;Sheila Weinmann;Michael Leo;Jess Savala;Steven C. Shivers;Karuna Mittal;Troy Bremer

April 26th 2023

40 Characterization of Recurrence Risk After Lumpectomy and Radiotherapy in HER2-Positive Ductal Carcinoma in Situ of the Breast Using a 7-Gene Predictive Biosignature: Implications for the NSABP-B43 Trial Results

Frank A. Vicini, MD;Chirag Shah, MD;Rachel Rabinovitch, MD;Pat W. Whitworth;Julie A. Margenthaler, MD;Brian Czerniecki;David J. Dabbs;Sheila Weinmann;Michael Leo;G. Bruce Mann;Fredrik Wärnberg;Jess Savala;Steven C. Shivers;Karuna Mittal;Troy Bremer

April 26th 2023

Molecular Profiling Assays in Breast Cancer: Beyond Prime Time and Into Syndication

Julie A. Margenthaler, MD;Amy E. Cyr, MD

April 17th 2012

Future randomized studies should focus on determining which patients benefit most from the inclusion of molecular diagnostics in treatment decision making and on the development of treatment algorithms that incorporate patient factors, histologic and biologic findings, and molecular markers.

Margin Status Following Partial Mastectomy: One Size Does Not Fit All!

Julie A. Margenthaler, MD;V. Suzanne Klimberg, MD

September 14th 2011

Breast-conserving therapy (BCT), which includes wide local excision of the tumor followed by irradiation, has become a standard treatment option for women with early-stage invasive breast cancer.